{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:36:22Z","timestamp":1793320582652,"version":"4.5.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Rates of overdose deaths involving synthetic opioids remain high, increasingly involve stimulants combined with opioids, and are increasing rapidly in racially and ethnically minoritized communities, yet little is known about access to harm reduction and treatment services in these groups.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To characterize access and barriers to harm reduction and treatment in a racially and ethnically diverse population of people who use drugs.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A cross-sectional telephone survey of people recruited from 39 treatment, harm reduction, and social service organizations in Milwaukee County, Wisconsin; Flint and Detroit, Michigan; and statewide in New Jersey was conducted from January 30 to July 28, 2023. Adults who used cocaine, methamphetamine, or opioids in the past 30 days called a study hotline and completed an interview in English or Spanish.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Overdose experience, drug types used (opioids only, stimulants only, and polysubstance), and social risk factors (eg, financial instability and criminal legal involvement).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Recent use of any harm reduction services, fentanyl test strips, naloxone possession, treatment, and self-reported barriers to services.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the total sample of 1240 adults, 486 (39.2%) were Black non-Hispanic, 183 (14.8%) were Hispanic, and 464 (37.4%) were White non-Hispanic. In the past 30 days, 826 individuals (66.6%) were polysubstance users, 135 (10.9%) used only opioids, and 279 (22.5%) used only stimulants. A total of 349 respondents (28.1%) experienced a prior-year overdose. Compared with those without a prior-year overdose, people with overdose were more likely to possess naloxone (80.7% vs 68.2%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), possess fentanyl test strips (36.8% vs 23.5%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and use harm reduction services (63.4% vs 53.0%;\n P<\/jats:italic>\n \u2009=\u2009.003), while differences in treatment use were nonsignificant (52.0% vs 46.6%;\n P<\/jats:italic>\n \u2009=\u2009.24). Among stimulant-only users, 51.4% possessed naloxone compared with 77.3% of opioid-only users (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and 77.6% of polysubstance users (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), with similar disparities in fentanyl test strip possession.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cross-sectional study of people who used drugs in the past 30 days, findings highlighted low use of harm reduction and treatment services among people who use stimulants. Additional communication regarding their importance may help increase the use of the services amidst a rapidly changing drug supply.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.27241","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T11:00:55Z","timestamp":1723460455000},"page":"e2427241","source":"Crossref","is-referenced-by-count":32,"title":["Harm Reduction and Treatment Among People at High Risk of Overdose"],"prefix":"10.1001","volume":"7","author":[{"given":"Sachini","family":"Bandara","sequence":"first","affiliation":[{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Byrne","sequence":"additional","affiliation":[{"name":"Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Berman","sequence":"additional","affiliation":[{"name":"Pacific Institute for Research and Evaluation, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Hurst","sequence":"additional","affiliation":[{"name":"Vital Strategies, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionna","family":"King","sequence":"additional","affiliation":[{"name":"Vital Strategies, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason B.","family":"Gibbons","sequence":"additional","affiliation":[{"name":"The University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia K.","family":"Sugarman","sequence":"additional","affiliation":[{"name":"Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Livingston","sequence":"additional","affiliation":[{"name":"Pacific Institute for Research and Evaluation, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Kerins","sequence":"additional","affiliation":[{"name":"Vital Strategies, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Hulsey","sequence":"additional","affiliation":[{"name":"Vital Strategies, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Alves","sequence":"additional","affiliation":[{"name":"Vital Strategies, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Saloner","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"zoi240842r3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis.","volume":"71","author":"Ciccarone","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi240842r4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/epirev\/mxaa011","article-title":"The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms.","volume":"42","author":"Jones","year":"2020","journal-title":"Epidemiol Rev"},{"issue":"10","key":"zoi240842r5","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.7326\/M23-2001","article-title":"Xylazine adulteration of the heroin-fentanyl drug supply: a narrative review.","volume":"176","author":"D\u2019Orazio","year":"2023","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi240842r6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0033354919887741","article-title":"The emerging role of toxic adulterants in street drugs in the US illicit opioid crisis.","volume":"135","author":"Singh","year":"2020","journal-title":"Public Health Rep"},{"issue":"29","key":"zoi240842r7","doi-asserted-by":"publisher","first-page":"940","DOI":"10.15585\/mmwr.mm7129e2","article-title":"Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics\u201425 states and the District of Columbia, 2019-2020.","volume":"71","author":"Kariisa","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi240842r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100052","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? using multiplier approaches to estimate prevalence for an unknown population size.","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"10","key":"zoi240842r9","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1111\/add.v116.10","article-title":"Heroin use cannot be measured adequately with a general population survey.","volume":"116","author":"Reuter","year":"2021","journal-title":"Addiction"},{"issue":"11","key":"zoi240842r10","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1001\/jamapsychiatry.2022.2756","article-title":"Estimating the prevalence of substance use disorders in the US using the benchmark multiplier method.","volume":"79","author":"Mojtabai","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"zoi240842r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the US? a yearly assessment from 2010 to 2019.","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi240842r12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12954-022-00720-7","article-title":"Characteristics and context of fentanyl test strip use among syringe service clients in southern Wisconsin.","volume":"19","author":"Tilhou","year":"2022","journal-title":"Harm Reduct J"},{"issue":"1","key":"zoi240842r13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12954-019-0311-9","article-title":"Harm reduction measures employed by people using opioids with suspected fentanyl exposure in Boston, Baltimore, and Providence.","volume":"16","author":"Rouhani","year":"2019","journal-title":"Harm Reduct J"},{"issue":"1","key":"zoi240842r14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12954-018-0213-2","article-title":"High willingness to use rapid fentanyl test strips among young adults who use drugs.","volume":"15","author":"Krieger","year":"2018","journal-title":"Harm Reduct J"},{"key":"zoi240842r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104063","article-title":"Understanding intentionality of fentanyl use and drug overdose risk: findings from a mixed methods study of people who inject drugs in New York City.","volume":"118","author":"McKnight","year":"2023","journal-title":"Int J Drug Policy"},{"key":"zoi240842r16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.drugpo.2017.05.023","article-title":"Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study.","volume":"46","author":"Carroll","year":"2017","journal-title":"Int J Drug Policy"},{"key":"zoi240842r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107581","article-title":"Take-home naloxone possession among people who inject drugs in rural West Virginia.","volume":"204","author":"Allen","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi240842r18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12954-022-00604-w","article-title":"Naloxone protection, social support, network characteristics, and overdose experiences among a cohort of people who use illicit opioids in New York City.","volume":"19","author":"Bennett","year":"2022","journal-title":"Harm Reduct J"},{"key":"zoi240842r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107743","article-title":"Understanding disparities in access to naloxone among people who inject drugs in Southeast Michigan using respondent driven sampling.","volume":"206","author":"Ong","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi240842r20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jsat.2017.10.008","article-title":"Factors associated with naloxone administration in an opioid dependent sample.","volume":"84","author":"Kenney","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"zoi240842r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.102642","article-title":"Polysubstance use in rural West Virginia: associations between latent classes of drug use, overdose, and take-home naloxone.","volume":"76","author":"Schneider","year":"2020","journal-title":"Int J Drug Policy"},{"key":"zoi240842r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103147","article-title":"\u201cI probably got a minute\u201d: perceptions of fentanyl test strip use among people who use stimulants.","volume":"92","author":"Reed","year":"2021","journal-title":"Int J Drug Policy"},{"key":"zoi240842r23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jsat.2019.10.005","article-title":"Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine.","volume":"109","author":"Tsui","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"zoi240842r24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/ajad.v30.2","article-title":"Increasing heroin-methamphetamine (goofball) use and related morbidity among Seattle area people who inject drugs.","volume":"30","author":"Glick","year":"2021","journal-title":"Am J Addict"},{"issue":"1","key":"zoi240842r25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nyas.v1508.1","article-title":"Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction.","volume":"1508","author":"Jones","year":"2022","journal-title":"Ann N Y Acad Sci"},{"issue":"10209","key":"zoi240842r26","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/S0140-6736(19)32230-5","article-title":"Responding to global stimulant use: challenges and opportunities.","volume":"394","author":"Farrell","year":"2019","journal-title":"Lancet"},{"key":"zoi240842r27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2018.06.004","article-title":"Risks of fatal opioid overdose during the first year following nonfatal overdose.","volume":"190","author":"Olfson","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"zoi240842r28","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jamapsychiatry.2020.1689","article-title":"Predictive modeling of opioid overdose using linked statewide medical and criminal justice data.","volume":"77","author":"Saloner","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"zoi240842r29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jsat.2018.04.004","article-title":"Patient predictors of substance use disorder treatment initiation in primary care.","volume":"90","author":"Ober","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"1-2","key":"zoi240842r30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2010.10.016","article-title":"Antecedents and correlates of methadone treatment entry: a comparison of out-of-treatment and in-treatment cohorts.","volume":"115","author":"Schwartz","year":"2011","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"zoi240842r31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1046\/j.1360-0443.2001.9657056.x","article-title":"Factors affecting the initiation of substance abuse treatment in managed care.","volume":"96","author":"Weisner","year":"2001","journal-title":"Addiction"},{"issue":"2","key":"zoi240842r32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/08897077.2019.1572052","article-title":"Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?","volume":"40","author":"Doernberg","year":"2019","journal-title":"Subst Abus"},{"key":"zoi240842r33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","article-title":"Opioid substitution therapy: lowering the treatment thresholds.","volume":"161","author":"Kourounis","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi240842r34","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s11414-013-9387-2","article-title":"The relationship of state Medicaid coverage to Medicaid acceptance among substance abuse providers in the United States.","volume":"41","author":"Andrews","year":"2014","journal-title":"J Behav Health Serv Res"},{"key":"zoi240842r35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2019.04.002","article-title":"Medicaid coverage in substance use disorder treatment after the Affordable Care Act.","volume":"102","author":"Andrews","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"zoi240842r36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jsat.2018.01.010","article-title":"Do benefits restrictions limit Medicaid acceptance in addiction treatment? results from a national study.","volume":"87","author":"Andrews","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"zoi240842r37","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2105\/AJPH.2011.300558","article-title":"The associations of clinicians\u2019 implicit attitudes about race with medical visit communication and patient ratings of interpersonal care.","volume":"102","author":"Cooper","year":"2012","journal-title":"Am J Public Health"},{"key":"zoi240842r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104289","article-title":"Updates on syringe coverage and service uptake among needle and syringe programs in the United States, 2019-2020.","volume":"123","author":"Tookes","year":"2024","journal-title":"Int J Drug Policy"},{"key":"zoi240842r39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.drugpo.2019.04.006","article-title":"Syringe services programs: an examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the US.","volume":"70","author":"Jones","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi240842r40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12954-023-00782-1","article-title":"Attitudes and experiences with fentanyl contamination of methamphetamine: exploring self-reports and urine toxicology among persons who use methamphetamine and other drugs.","volume":"20","author":"Daniulaityte","year":"2023","journal-title":"Harm Reduct J"},{"key":"zoi240842r1","unstructured":"Ahmad? F, Cisewski? J, Rossen? J, Sutton? P. Provisional drug overdose death counts. National Center for Health Statistics. 2023. Accessed October 11, 2023. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi240842r2","unstructured":"Spencer? M, Minino? A, Warner? M. Drug overdose deaths in the United States, 2001\u20132021. Centers for Disease Control and Prevention, US Department of Health and Human Services. 2022. Accessed October 15, 2023. https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db457.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2822210\/bandara_2024_oi_240842_1722871497.99655.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T11:00:59Z","timestamp":1723460459000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2822210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.27241","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]}}}